Ergot Alkaloid Pharmacology

Correct Answer

C — Uterotonics

Rationale

Methylergonovine, oxytocin, and carboprost are all classified as uterotonics — drugs that stimulate uterine smooth muscle contraction. Each agent works through a different receptor mechanism, which is why they can be used sequentially or in combination when a single agent is insufficient to control postpartum hemorrhage. Tocolytics are drugs that inhibit uterine contractions and are used to delay preterm labor — the opposite pharmacological goal. Oxytocin receptor antagonists such as atosiban block uterine contractions and are used as tocolytics. Beta-2 adrenergic agonists such as terbutaline also relax uterine smooth muscle and are classified as tocolytics, not uterotonics.

Correct Answer

A — Intramuscular

Rationale

Methylergonovine is administered by intramuscular injection for routine postpartum hemorrhage prevention and treatment. The intramuscular route provides reliable absorption with onset of action within two to five minutes — fast enough for acute hemorrhage management while avoiding the cardiovascular risks associated with rapid intravenous delivery. Intravenous administration is possible in emergencies but carries a substantially higher risk of severe hypertension because rapid delivery to central receptors produces intense vasoconstriction; when used intravenously it must be given slowly with careful blood pressure monitoring. Sublingual and transdermal routes are not used for methylergonovine in acute postpartum hemorrhage management.

Correct Answer

D — Second-line agent, added when oxytocin alone does not produce adequate uterine tone

Rationale

Methylergonovine is classified as a second-line uterotonic agent. Oxytocin is the first-line agent used routinely at the time of placental delivery in active management of the third stage of labor. When oxytocin alone does not produce adequate uterine tone — or when postpartum hemorrhage develops despite oxytocin — methylergonovine is added. The complementary receptor mechanisms of the two drugs make them a logical pairing: oxytocin acts through oxytocin receptors on the myometrium, while methylergonovine acts through alpha-adrenergic and serotonin type 2 receptors, providing additive uterotonic effect through pharmacologically distinct pathways. Methylergonovine is not first-line, not interchangeable with oxytocin as an equal alternative, and is not reserved for third-line use.

Correct Answer

B — Direct-acting uterotonics that stimulate the uterus without requiring an intermediate hormonal pathway

Rationale

Ergonovine and methylergonovine are classified as direct-acting uterotonics. They bind directly to alpha-adrenergic and serotonin type 2 receptors on myometrial smooth muscle cells and activate them without requiring endogenous oxytocin release, prostaglandin synthesis, or any intermediate hormonal step. This direct action distinguishes them mechanistically from agents that depend on endogenous mediators. It also means their uterotonic effect does not depend on the integrity of oxytocin receptor signaling — a pharmacologically distinct pathway that allows them to be used alongside oxytocin for additive effect. Indirect-acting, prostaglandin-mediated, and oxytocin-dependent classifications all describe mechanisms that ergonovine and methylergonovine do not use.

Correct Answer

C — Absolute contraindications — methylergonovine must not be used in any patient with hypertension or preeclampsia

Rationale

Hypertension in any form — including chronic hypertension, gestational hypertension, preeclampsia, and eclampsia — is an absolute contraindication to methylergonovine. The vasoconstriction produced by methylergonovine raises peripheral vascular resistance and increases blood pressure. In a patient whose blood pressure is already elevated, this additional increase can trigger hypertensive emergency, stroke, or cardiovascular collapse. Preeclampsia requires particular emphasis because it is the hypertensive condition most commonly encountered in the obstetric setting where methylergonovine would otherwise be indicated. When a patient has both preeclampsia and postpartum hemorrhage, oxytocin remains the appropriate uterotonic choice. These are not relative contraindications or precautions — they are absolute, and dose reduction does not make methylergonovine safe in hypertensive patients.

Correct Answer

A — Methylergonovine produces sustained tetanic contraction; oxytocin produces rhythmic phasic contractions

Rationale

Methylergonovine and oxytocin are both uterotonics but produce qualitatively different uterine contraction patterns. Methylergonovine produces sustained, tetanic contraction of the uterus — a continuous, non-relaxing contraction that mechanically compresses uterine blood vessels more continuously and is more effective at controlling hemorrhage. Oxytocin produces rhythmic, wave-like contractions that allow uterine relaxation between cycles, preserving some blood flow through the uterine vasculature between contractions. This distinction in contraction character reflects the different receptor mechanisms through which the two drugs act and has clinical implications for which agent is preferred in different obstetric situations.

Correct Answer

B — Simultaneous activation of alpha-adrenergic and serotonin type 2 receptors on myometrial smooth muscle cells increases intracellular calcium through parallel pathways, producing sustained tetanic contraction

Rationale

Methylergonovine produces uterine contraction through two receptor mechanisms acting simultaneously on myometrial smooth muscle cells. Alpha-adrenergic receptor activation increases intracellular calcium, triggering smooth muscle contraction. Serotonin type 2 receptor activation reinforces this effect through a parallel calcium-dependent pathway. The dual receptor engagement produces a sustained, tetanic contraction — qualitatively different from the rhythmic, wave-like contractions that oxytocin produces through its own receptor. Methylergonovine is a direct-acting uterotonic; its effect does not depend on endogenous oxytocin, prostaglandin synthesis, or dopamine receptor signaling. Oxytocin receptor activation, dopamine type 2 receptor-mediated adenylyl cyclase inhibition, and prostaglandin receptor-mediated phospholipase C activation describe mechanisms of other agents rather than methylergonovine.

Correct Answer

D — Methylergonovine produces sustained tetanic contraction that compresses uterine blood vessels continuously, whereas oxytocin produces rhythmic contractions that allow vessel relaxation and renewed bleeding between cycles

Rationale

The key difference between methylergonovine and oxytocin in hemorrhage control is the character of uterine contraction each produces. Oxytocin produces rhythmic, wave-like contractions that allow uterine relaxation between cycles, which preserves some blood flow through the uterine vasculature but also permits intervals during which vessels are not mechanically compressed. Methylergonovine produces sustained, tetanic contraction that keeps the uterine musculature contracted continuously, mechanically compressing the uterine blood vessels without relaxation intervals. This continuous mechanical compression is more effective at arresting active hemorrhage. The comparative advantage of methylergonovine is therefore mechanistic — it relates to contraction character rather than onset speed, receptor overlap with oxytocin, or plasma half-life.

Correct Answer

A — Methylergonovine produces systemic vasoconstriction that raises peripheral vascular resistance and blood pressure, risking hypertensive emergency in patients with pre-existing hypertension

Rationale

Methylergonovine activates alpha-adrenergic and serotonin type 2 receptors on vascular smooth muscle throughout the body, producing systemic vasoconstriction. This vasoconstriction raises peripheral vascular resistance and increases blood pressure. In a patient whose blood pressure is already elevated — including those with chronic hypertension, gestational hypertension, preeclampsia, or eclampsia — this additional pressure increase can trigger hypertensive emergency, manifesting as severe headache, visual changes, stroke, or hypertensive encephalopathy. The same vasoconstrictive mechanism that is useful in compressing uterine blood vessels becomes dangerous when applied systemically in a hypertensive patient. Dopamine type 2 receptor-mediated sodium retention, baroreceptor reflex blockade, and catecholamine release from adrenal chromaffin cells are not the mechanism of methylergonovine-induced hypertension.

Correct Answer

C — Methylergonovine produces sustained tetanic uterine contraction that would trap the placenta in a firmly contracted uterus before it can be delivered

Rationale

The timing contraindication for methylergonovine follows directly from its pharmacological mechanism. Methylergonovine produces sustained, tetanic contraction of the uterine musculature through alpha-adrenergic and serotonin type 2 receptor activation. If this contraction occurs before the placenta has separated and been delivered, the firmly contracted uterus traps the placenta, preventing its expulsion during the third stage of labor and potentially converting a normal delivery into a serious obstetric emergency requiring manual placental removal. Administered after placental delivery, the same tetanic contraction is beneficial — it compresses the uterine blood vessels and reduces postpartum hemorrhage. Fetal bradycardia from placental transfer, oxytocin receptor downregulation, and inhibition of placental prostaglandin synthesis are not the pharmacological basis for this timing requirement.

Correct Answer

B — Dopaminergic activity at the chemoreceptor trigger zone in the medulla stimulates the vomiting center, producing nausea and vomiting

Rationale

Although methylergonovine's primary clinical mechanism involves alpha-adrenergic and serotonin type 2 receptor activation on uterine and vascular smooth muscle, it retains dopaminergic activity from its ergot alkaloid backbone. This dopaminergic activity stimulates the chemoreceptor trigger zone — a specialized area in the medulla oblongata that detects emetic stimuli and activates the vomiting center. Nausea and vomiting from methylergonovine are generally self-limiting and manageable with antiemetic therapy. This is the same mechanism by which other ergot alkaloids and dopamine receptor agonists produce nausea. Alpha-adrenergic-mediated intestinal dysmotility, enterochromaffin serotonin release through gastrointestinal serotonin type 2 receptors, and mesenteric vasoconstriction each describe mechanisms of gastrointestinal disturbance that operate through pathways distinct from the chemoreceptor trigger zone mechanism responsible for methylergonovine-induced nausea.

Correct Answer

D — Azithromycin does not inhibit cytochrome P450 3A4, so it does not impair methylergonovine metabolism or raise plasma concentrations to toxic levels

Rationale

Methylergonovine is metabolized by cytochrome P450 3A4. Erythromycin and clarithromycin are potent cytochrome P450 3A4 inhibitors that block this metabolic pathway, causing methylergonovine plasma concentrations to rise to levels that produce severe vasoconstriction and hypertension. Azithromycin is a macrolide antibiotic that does not inhibit cytochrome P450 3A4. Because it leaves methylergonovine metabolism intact, plasma concentrations remain in the therapeutic range during co-administration and the risk of toxicity is avoided. This cytochrome P450 3A4 drug interaction applies to the obstetric ergot alkaloids — methylergonovine and ergonovine — as fully as it does to the migraine ergot alkaloids. Renal elimination, short duration of action, and enzyme induction do not explain azithromycin's safety in this context.

Correct Answer

A — Intravenous administration delivers drug rapidly to central vascular receptors, producing high peak concentrations and intense vasoconstriction that intramuscular absorption avoids by providing slower, more gradual drug delivery

Rationale

The cardiovascular risk difference between intravenous and intramuscular methylergonovine is pharmacokinetic in origin. Intravenous administration delivers the full dose directly into the bloodstream, producing rapid, high peak plasma concentrations that reach vascular alpha-adrenergic and serotonin type 2 receptors simultaneously throughout the body. This produces intense, acute vasoconstriction and a sharp rise in blood pressure. Intramuscular administration produces absorption over several minutes, generating a more gradual rise in plasma concentration and a less abrupt vasoconstrictive response. When intravenous administration is necessary in an emergency, the drug must be given slowly and with careful blood pressure monitoring to mitigate this risk. Pulmonary first-pass conversion to a more potent metabolite and access to different receptor subtypes via the pulmonary route are not established mechanisms for this difference.

Correct Answer

C — Methylergonovine's vasoconstrictive mechanism raises blood pressure and is absolutely contraindicated in preeclampsia, while oxytocin acts through its own receptor without raising peripheral vascular resistance

Rationale

Preeclampsia is an absolute contraindication to methylergonovine. The alpha-adrenergic and serotonin type 2 receptor activation that gives methylergonovine its uterotonic effect also produces systemic vasoconstriction that raises peripheral vascular resistance and blood pressure. In a patient with preeclampsia — already characterized by hypertension and end-organ vulnerability — this additional vasoconstrictive load can precipitate hypertensive emergency, stroke, or cardiovascular collapse. Oxytocin acts through a pharmacologically distinct oxytocin receptor on myometrial cells and does not produce the systemic vasoconstriction that makes methylergonovine dangerous in this setting. When further uterotonic therapy beyond oxytocin is needed in a patient with preeclampsia, carboprost or misoprostol are the agents of choice. The contraction character comparison is reversed — methylergonovine, not oxytocin, produces tetanic contraction. Alpha-adrenergic receptor downregulation in preeclampsia and blood-brain barrier penetration causing seizures are not established mechanisms for this clinical decision.

Correct Answer

B — Methylergonovine activates alpha-adrenergic and serotonin type 2 receptors on peripheral vascular smooth muscle, reducing blood flow in vessels that are already narrowed by vascular disease

Rationale

Peripheral vascular disease is a contraindication to methylergonovine for the same reason as coronary artery disease: the alpha-adrenergic and serotonin type 2 receptor activation that produces the drug's uterotonic effect also constricts blood vessels throughout the body. In a patient with peripheral vascular disease, the affected vessels are already narrowed by atherosclerosis or vasospasm and have reduced capacity to maintain adequate distal perfusion. Superimposing ergot-induced vasoconstriction on this baseline narrows the lumen further, potentially reducing blood flow below the threshold needed to sustain tissue viability in the extremities. The contraindication applies even when methylergonovine is being considered as an adjunct rather than a primary agent — the vasoconstrictive mechanism does not depend on whether oxytocin is also being used. Oxytocin receptor activation by methylergonovine, altered drug metabolism in vascular disease, and prostaglandin vasodilation blockade are not the mechanisms of this contraindication.

Correct Answer

D — Dopaminergic activity from methylergonovine's ergot backbone stimulates the chemoreceptor trigger zone in the medulla, activating the vomiting center and producing nausea

Rationale

Although methylergonovine's primary uterotonic mechanism involves alpha-adrenergic and serotonin type 2 receptor activation on myometrial smooth muscle, it retains dopaminergic activity from its ergot alkaloid backbone. This dopaminergic activity stimulates the chemoreceptor trigger zone — a specialized area in the medulla oblongata that detects emetic stimuli and signals the vomiting center. The nausea and vomiting occur even when the drug is working as intended, as in this patient whose uterine tone and blood pressure are satisfactory. These effects are generally self-limiting and manageable with antiemetic therapy. Gastric mucosal ischemia through alpha-adrenergic receptor activation, accelerated gastric emptying through gastrointestinal serotonin type 2 receptor activation, and mesenteric vasoconstriction causing enterocyte ischemia each describe gastrointestinal mechanisms that are distinct from the chemoreceptor trigger zone pathway responsible for this adverse effect.

Correct Answer

A — Prolonged oxytocin exposure causes downregulation of oxytocin receptors on myometrial cells, reducing the uterine response to further oxytocin; methylergonovine acts through alpha-adrenergic and serotonin type 2 receptors that remain fully responsive

Rationale

Prolonged stimulation of a receptor by an agonist typically leads to receptor downregulation — a reduction in receptor number or responsiveness as the cell adapts to sustained activation. After a prolonged high-dose oxytocin infusion, oxytocin receptors on myometrial smooth muscle cells become downregulated, and the uterus loses its responsiveness to further oxytocin stimulation. This is a recognized clinical phenomenon in patients who have received extended oxytocin augmentation and then develop postpartum hemorrhage. Methylergonovine bypasses this desensitized receptor pathway entirely by acting through alpha-adrenergic receptors and serotonin type 2 receptors on myometrial cells — receptors that have not been exposed to prolonged agonist stimulation and remain fully responsive. The pharmacologically distinct mechanism of methylergonovine is precisely what makes it a useful second-line agent in this situation. Myometrial calcium depletion, prostaglandin synthesis inhibition by oxytocin, and competitive alpha-adrenergic receptor blockade by oxytocin are not established mechanisms for oxytocin refractoriness.

Correct Answer

C — Methylergonovine acts through alpha-adrenergic and serotonin type 2 receptors on myometrial smooth muscle — a pharmacologically distinct pathway from the oxytocin receptor — producing sustained tetanic contraction rather than the phasic pattern that oxytocin receptor signaling generates

Rationale

The difference in contraction character between methylergonovine and oxytocin reflects their distinct receptor mechanisms. Oxytocin acts through oxytocin receptors on myometrial cells, producing rhythmic, wave-like contractions that allow uterine relaxation between cycles. Methylergonovine activates alpha-adrenergic receptors and serotonin type 2 receptors on myometrial smooth muscle cells — neither of which is the oxytocin receptor. This pharmacologically distinct pathway produces sustained, tetanic contraction that keeps the uterine musculature contracted without relaxation intervals. The resulting continuous mechanical compression of uterine blood vessels is more effective at controlling active hemorrhage than the intermittent compression that oxytocin's phasic contractions provide. The difference in contraction character is mechanistic — it arises from receptor pathway differences, not from plasma half-life, receptor affinity comparisons with oxytocin, or ion channel effects.